高密度脂蛋白受体SR-BI：动脉粥样硬化的新治疗靶点？

The HDL receptor SR-BI: a new therapeutic target for atherosclerosis?

作者信息

Acton S L, Kozarsky K F, Rigotti A

机构信息

Cardiovascular Biology, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA 02139, USA.

出版信息

Mol Med Today. 1999 Dec;5(12):518-24. doi: 10.1016/s1357-4310(99)01600-7.

DOI:10.1016/s1357-4310(99)01600-7

PMID:10562717

Abstract

Although high-density lipoprotein (HDL) metabolism is a crucial process for cholesterol homeostasis and coronary heart disease, therapeutic approaches for selective modification of plasma HDL levels are not currently available. The discovery of well-defined cell-surface HDL receptors should provide new avenues for treatment of atherosclerotic cardiovascular disease. In fact, SR-BI, a recently identified receptor for selective HDL cholesterol uptake, is relevant for physiological processes (for example, HDL metabolism, steroidogenesis and biliary cholesterol secretion) and pathophysiological conditions (for example, atherosclerosis) in animal models. If SR-BI has similar activities in humans, it might represent a new therapeutic target for atherosclerosis.

摘要

尽管高密度脂蛋白（HDL）代谢是胆固醇稳态和冠心病的关键过程，但目前尚无选择性改变血浆HDL水平的治疗方法。明确的细胞表面HDL受体的发现应为动脉粥样硬化性心血管疾病的治疗提供新途径。事实上，SR-BI是最近发现的一种选择性摄取HDL胆固醇的受体，与动物模型中的生理过程（如HDL代谢、类固醇生成和胆汁胆固醇分泌）和病理生理状况（如动脉粥样硬化）相关。如果SR-BI在人类中具有类似活性，它可能代表动脉粥样硬化的一个新治疗靶点。